250 related articles for article (PubMed ID: 32270286)
1. Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Chan CWH; Law BMH; So WKW; Chow KM; Waye MMY
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1395-1404. PubMed ID: 32270286
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 gene variants: association with breast cancer specific survival in a cohort of breast cancer patients from the United Kingdom treated with adjuvant tamoxifen.
Abraham JE; Maranian MJ; Driver KE; Platte R; Kalmyrzaev B; Baynes C; Luccarini C; Shah M; Ingle S; Greenberg D; Earl HM; Dunning AM; Pharoah PD; Caldas C
Breast Cancer Res; 2010; 12(4):R64. PubMed ID: 20731819
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of endocrine therapy in breast cancer.
Weinshilboum R
Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and breast cancer endocrine therapy: CYP2D6 as a predictive factor for tamoxifen metabolism and drug response?
Stearns V; Rae JM
Expert Rev Mol Med; 2008 Nov; 10():e34. PubMed ID: 19019258
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response.
Goetz MP; Kamal A; Ames MM
Clin Pharmacol Ther; 2008 Jan; 83(1):160-6. PubMed ID: 17882159
[TBL] [Abstract][Full Text] [Related]
6. Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer.
Bezerra LS; Santos-Veloso MAO; Bezerra Junior NDS; Fonseca LCD; Sales WLA
Rev Bras Ginecol Obstet; 2018 Dec; 40(12):794-799. PubMed ID: 30536272
[TBL] [Abstract][Full Text] [Related]
7. Should CYP2D6 be genotyped when treating with tamoxifen?
Del Re M; Rofi E; Citi V; Fidilio L; Danesi R
Pharmacogenomics; 2017 Jun; 18(8):755-756. PubMed ID: 28593824
[TBL] [Abstract][Full Text] [Related]
8. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen.
Goetz MP; Knox SK; Suman VJ; Rae JM; Safgren SL; Ames MM; Visscher DW; Reynolds C; Couch FJ; Lingle WL; Weinshilboum RM; Fritcher EG; Nibbe AM; Desta Z; Nguyen A; Flockhart DA; Perez EA; Ingle JN
Breast Cancer Res Treat; 2007 Jan; 101(1):113-21. PubMed ID: 17115111
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of tamoxifen and irinotecan therapies.
Algeciras-Schimnich A; O'Kane DJ; Snozek CL
Clin Lab Med; 2008 Dec; 28(4):553-67. PubMed ID: 19059062
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of Aromatase Inhibitors in Endocrine Responsive Breast Cancer: Lessons Learnt from Tamoxifen and CYP2D6 Genotyping.
Baatjes KJ; Conradie M; Apffelstaedt JP; Kotze MJ
Anticancer Agents Med Chem; 2017; 17(13):1805-1813. PubMed ID: 28403774
[TBL] [Abstract][Full Text] [Related]
11. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
Zembutsu H
Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
[TBL] [Abstract][Full Text] [Related]
13. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance.
Higgins MJ; Stearns V
Curr Oncol Rep; 2010 Jan; 12(1):7-15. PubMed ID: 20425602
[TBL] [Abstract][Full Text] [Related]
14. Lack of any association between functionally significant CYP2D6 polymorphisms and clinical outcomes in early breast cancer patients receiving adjuvant tamoxifen treatment.
Park IH; Ro J; Park S; Lim HS; Lee KS; Kang HS; Jung SY; Lee S
Breast Cancer Res Treat; 2012 Jan; 131(2):455-61. PubMed ID: 21437611
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.
Gaston C; Kolesar J
Clin Adv Hematol Oncol; 2008 Nov; 6(11):825-33. PubMed ID: 19194367
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
Kaplan M; Mahon SM
Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
[TBL] [Abstract][Full Text] [Related]
17. The ethics of CYP2D6 testing for patients considering tamoxifen.
Hartman AR; Helft P
Breast Cancer Res; 2007; 9(2):103. PubMed ID: 17433116
[TBL] [Abstract][Full Text] [Related]
18. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
Damkier P
Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
[TBL] [Abstract][Full Text] [Related]
19. CYP2D6 pharmacogenomics of tamoxifen treatment.
; ;
Technol Eval Cent Assess Program Exec Summ; 2014 Jan; 28(8):1-4. PubMed ID: 24730084
[No Abstract] [Full Text] [Related]
20. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes.
Singh MS; Francis PA; Michael M
Breast; 2011 Apr; 20(2):111-8. PubMed ID: 21185724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
